<DOC>
	<DOCNO>NCT00354263</DOCNO>
	<brief_summary>This study single centre , single blind , placebo ( step 1 ) reference ( step 2 ) randomise study . Healthy young male volunteer receive single ascend dose IMP321 step ( 4 dos test : 3 , 10 , 30 100 µg ) . In step 1 , IMP321 give alone test versus placebo ( physiological saline ) . In step 2 , association IMP321 + Agrippal ( commercially available flu vaccine ) test versus Agrippal alone .</brief_summary>
	<brief_title>Phase I Study IMP321 Given Alone Adjuvant Reference Flu Antigen</brief_title>
	<detailed_description>This study divide two step : Step 1 ( 20 volunteer ) : IMP321 give alone test versus placebo ( physiological saline ) In first step , 4 group dos ( four subject ) evaluate versus placebo group 4 subject : - Group IMP321 alone 3 µg , - Group IMP321 alone 10 µg , - Group IMP321 alone 30 µg , - Group IMP321 alone 100 µg . In order complete group , four successive cohort volunteer study : Cohort A correspond dose 3 µg include : - 4 subject treat IMP321 3 µg alone - 1 subject treat placebo If tolerability cohort acceptable , follow cohort do . Cohort B correspond dose 10 µg include : - 4 subject treat IMP321 10 µg alone - 1 subject treat placebo If tolerability cohort acceptable , follow cohort dose . Cohort C correspond dose 30 µg include : - 4 subject treat IMP321 30 µg alone - 1 subject treat placebo If tolerability cohort acceptable , follow cohort do . Cohort D correspond dose 100 µg include : - 4 subject treat IMP321 100 µg alone - 1 subject treat placebo Step 2 ( 40 volunteer ) : The association IMP321 + Agrippal test versus Agrippal alone . In second step , 4 group dos ( eight subject ) evaluate versus reference group ( Agrippal + physiological saline ) 8 subject : - Group Agrippal + 3 µg IMP321 , - Group Agrippal + 10 µg IMP321 , - Group Agrippal + 30 µg IMP321 , - Group Agrippal + 100 µg IMP321 . In order complete group , four successive cohort volunteer study . Cohort A correspond dose 3 µg IMP321 include : - 8 subject treat Agrippal + IMP321 3 µg - 2 subject treat Agrippal + physiological saline If tolerability cohort acceptable , follow cohort do . Cohort B correspond dose 10 µg IMP321 include : - 8 subject treat Agrippal + IMP321 10 µg - 2 subject treat Agrippal + physiological saline If tolerability cohort acceptable , follow cohort do . Cohort C correspond dose 30 µg IMP321 include : - 8 subject treat Agrippal + IMP321 30 µg - 2 subject treat Agrippal + physiological saline If tolerability cohort acceptable , follow cohort do . Cohort D correspond dose 100 µg IMP321 include : - 8 subject treat Agrippal + IMP321 100 µg - 2 subject treat Agrippal + physiological saline . This study single centre , single blind , placebo ( step 1 ) reference ( step 2 ) randomise study . Healthy young male volunteer receive single ascend dose IMP321 step . Treatments administer subcutaneous injection morning Day 1 . The injection do subcutaneously ( s.c. ) deltoid area non dominant arm . The pharmacokinetic analysis perform IMP321-specific ELISA test sample collect 4 volunteer receive 100 µg IMP321 alone . Blood sample take morning Day 1 dose 0.5 , 1 , 4 , 24 48 h dosing . Blood sample ( T cell assay ) serum sample ( hLAG-3Ig- HA-specific antibody detection ELISA ) take morning Days 1 , 29 57 . Monitoring occurrence adverse event ( AE ) , change physical examination , vital sign ( blood pressure , pulse rate , respiration ) , electrocardiogram ( ECG ) clinical laboratory test ( biochemistry , haematology , urinalysis ) perform dose study drug ass safety tolerability .</detailed_description>
	<criteria>able give write informed consent ; healthy male volunteer age 18 40 year ; body mass index ( weight/height² ) range 18 30 kg/m² ; register French Social Security agreement French Law ( Huriet Law : N° 88.1138 20.12.88 ) biomedical experimentation ; able comply protocol requirement , include blood urine sample collection define protocol ; flu vaccination last two year . direct question physical examination evidence clinically significant acute chronic disease , include know suspected HIV , HBV HCV infection ; clinically significant abnormality follow review prestudy laboratory test full physical examination ; receive experimental drug within exclusion period define National Register Healthy Volunteers French Ministry Health ; forfeit freedom administrative legal award guardianship ; unwilling give inform consent ; present positive laboratory test Hepatitis B surface antigen ( HbsAg ) , HBc antibody , HIV 1 2 antibody HCV antibody ; history allergy intolerance study drug ; history serious allergy , asthma , allergic skin rash sensitivity drug ; know suspected alcohol drug abuser ; present positive laboratory test urine drug screening ( opiate , barbiturate , amphetamine , cannabis ) ; undergo surgery donate blood within 1 month prior start study ; take prescribed counter drug ( include antacid drug ) , exception paracetamol ( 3 g per day ) within 1 week prior first dose administration ; receive drug know affect hepatic metabolism like cimetidine , ketoconazole , fluconazole , itraconazole , phenytoin , rifampicin , rifabutin within 1 month prior first dose administration ; receive drug know affect renal tubular secretion like probenecid , betalactam antibiotic within 2 week prior first dose administration ; present clinical condition prior therapy , opinion investigator , make subject unsuitable study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Healthy male volunteer</keyword>
	<keyword>IMP321</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Monotherapy</keyword>
	<keyword>Pharmacokinetics/Pharmacodynamics</keyword>
</DOC>